Literature DB >> 25428260

KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype.

A Clipson1, M Wang1, L de Leval2, M Ashton-Key3, A Wotherspoon4, G Vassiliou5, N Bolli5, C Grove6, S Moody1, L Escudero-Ibarz1, G Gundem6, K Brugger7, X Xue1, E Mi1, A Bench8, M Scott8, H Liu9, G Follows8, E F Robles10, J A Martinez-Climent10, D Oscier11, A J Watkins12, M-Q Du1.   

Abstract

To characterise the genetics of splenic marginal zone lymphoma (SMZL), we performed whole exome sequencing of 16 cases and identified novel recurrent inactivating mutations in Kruppel-like factor 2 (KLF2), a gene whose deficiency was previously shown to cause splenic marginal zone hyperplasia in mice. KLF2 mutation was found in 40 (42%) of 96 SMZLs, but rarely in other B-cell lymphomas. The majority of KLF2 mutations were frameshift indels or nonsense changes, with missense mutations clustered in the C-terminal zinc finger domains. Functional assays showed that these mutations inactivated the ability of KLF2 to suppress NF-κB activation by TLR, BCR, BAFFR and TNFR signalling. Further extensive investigations revealed common and distinct genetic changes between SMZL with and without KLF2 mutation. IGHV1-2 rearrangement and 7q deletion were primarily seen in SMZL with KLF2 mutation, while MYD88 and TP53 mutations were nearly exclusively found in those without KLF2 mutation. NOTCH2, TRAF3, TNFAIP3 and CARD11 mutations were observed in SMZL both with and without KLF2 mutation. Taken together, KLF2 mutation is the most common genetic change in SMZL and identifies a subset with a distinct genotype characterised by multi-genetic changes. These different genetic changes may deregulate various signalling pathways and generate cooperative oncogenic properties, thereby contributing to lymphomagenesis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25428260     DOI: 10.1038/leu.2014.330

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  51 in total

1.  Notch-RBP-J signaling is involved in cell fate determination of marginal zone B cells.

Authors:  Kenji Tanigaki; Hua Han; Norio Yamamoto; Kei Tashiro; Masaya Ikegawa; Kazuki Kuroda; Akira Suzuki; Toru Nakano; Tasuku Honjo
Journal:  Nat Immunol       Date:  2002-04-22       Impact factor: 25.606

2.  Oncogenically active MYD88 mutations in human lymphoma.

Authors:  Vu N Ngo; Ryan M Young; Roland Schmitz; Sameer Jhavar; Wenming Xiao; Kian-Huat Lim; Holger Kohlhammer; Weihong Xu; Yandan Yang; Hong Zhao; Arthur L Shaffer; Paul Romesser; George Wright; John Powell; Andreas Rosenwald; Hans Konrad Muller-Hermelink; German Ott; Randy D Gascoyne; Joseph M Connors; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; Jan Delabie; Erlend B Smeland; Richard I Fisher; Rita M Braziel; Raymond R Tubbs; J R Cook; Denny D Weisenburger; Wing C Chan; Louis M Staudt
Journal:  Nature       Date:  2010-12-22       Impact factor: 49.962

3.  Oncogenic CARD11 mutations in human diffuse large B cell lymphoma.

Authors:  Georg Lenz; R Eric Davis; Vu N Ngo; Lloyd Lam; Thaddeus C George; George W Wright; Sandeep S Dave; Hong Zhao; Weihong Xu; Andreas Rosenwald; German Ott; Hans Konrad Muller-Hermelink; Randy D Gascoyne; Joseph M Connors; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; Jan Delabie; Erlend B Smeland; Richard I Fisher; Wing C Chan; Louis M Staudt
Journal:  Science       Date:  2008-03-06       Impact factor: 47.728

4.  TLR2- and nucleotide-binding oligomerization domain 2-dependent Krüppel-like factor 2 expression downregulates NF-kappa B-related gene expression.

Authors:  Janine Zahlten; Robert Steinicke; Bastian Opitz; Julia Eitel; Philippe Dje N'guessan; Maya Vinzing; Martin Witzenrath; Bernd Schmeck; Sven Hammerschmidt; Norbert Suttorp; Stefan Hippenstiel
Journal:  J Immunol       Date:  2010-06-04       Impact factor: 5.422

Review 5.  The noncanonical NF-κB pathway.

Authors:  Shao-Cong Sun
Journal:  Immunol Rev       Date:  2012-03       Impact factor: 12.988

6.  BCR and TLR signaling pathways are recurrently targeted by genetic changes in splenic marginal zone lymphomas.

Authors:  Qingguo Yan; Yuanxue Huang; A James Watkins; Sylvia Kocialkowski; Naiyan Zeng; Rifat A Hamoudi; Peter G Isaacson; Laurence de Leval; Andrew Wotherspoon; Ming-Qing Du
Journal:  Haematologica       Date:  2011-11-18       Impact factor: 9.941

7.  Follicular B cell trafficking within the spleen actively restricts humoral immune responses.

Authors:  Kristen L Hoek; Laura E Gordy; Patrick L Collins; Vrajesh V Parekh; Thomas M Aune; Sebastian Joyce; James W Thomas; Luc Van Kaer; Eric Sebzda
Journal:  Immunity       Date:  2010-08-05       Impact factor: 31.745

Review 8.  Marginal zone B cells: virtues of innate-like antibody-producing lymphocytes.

Authors:  Andrea Cerutti; Montserrat Cols; Irene Puga
Journal:  Nat Rev Immunol       Date:  2013-02       Impact factor: 53.106

9.  Splenic marginal zone lymphoma: a prognostic model for clinical use.

Authors:  Luca Arcaini; Mario Lazzarino; Nora Colombo; Sara Burcheri; Emanuela Boveri; Marco Paulli; Enrica Morra; Marcello Gambacorta; Sergio Cortelazzo; Alessandra Tucci; Marco Ungari; Achille Ambrosetti; Fabio Menestrina; Lorella Orsucci; Domenico Novero; Alessandro Pulsoni; Maurizio Frezzato; Gianluca Gaidano; Daniele Vallisa; Viviana Minardi; Claudio Tripodo; Vincenzo Callea; Luca Baldini; Francesco Merli; Massimo Federico; Vito Franco; Emilio Iannitto
Journal:  Blood       Date:  2006-02-21       Impact factor: 22.113

10.  The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development.

Authors:  Davide Rossi; Vladimir Trifonov; Marco Fangazio; Alessio Bruscaggin; Silvia Rasi; Valeria Spina; Sara Monti; Tiziana Vaisitti; Francesca Arruga; Rosella Famà; Carmela Ciardullo; Mariangela Greco; Stefania Cresta; Daniela Piranda; Antony Holmes; Giulia Fabbri; Monica Messina; Andrea Rinaldi; Jiguang Wang; Claudio Agostinelli; Pier Paolo Piccaluga; Marco Lucioni; Fabrizio Tabbò; Roberto Serra; Silvia Franceschetti; Clara Deambrogi; Giulia Daniele; Valter Gattei; Roberto Marasca; Fabio Facchetti; Luca Arcaini; Giorgio Inghirami; Francesco Bertoni; Stefano A Pileri; Silvia Deaglio; Robin Foà; Riccardo Dalla-Favera; Laura Pasqualucci; Raul Rabadan; Gianluca Gaidano
Journal:  J Exp Med       Date:  2012-08-13       Impact factor: 14.307

View more
  56 in total

Review 1.  Ontogeny, Genetics, Molecular Biology, and Classification of B- and T-Cell Non-Hodgkin Lymphoma.

Authors:  Russell James Hubbard Ryan; Ryan Alan Wilcox
Journal:  Hematol Oncol Clin North Am       Date:  2019-05-18       Impact factor: 3.722

Review 2.  NF-κB signaling pathway and its potential as a target for therapy in lymphoid neoplasms.

Authors:  Li Yu; Ling Li; L Jeffrey Medeiros; Ken H Young
Journal:  Blood Rev       Date:  2016-10-13       Impact factor: 8.250

3.  Clinical and diagnostic relevance of NOTCH2-and KLF2-mutations in splenic marginal zone lymphoma.

Authors:  Yolanda Campos-Martín; Nerea Martínez; Azahara Martínez-López; Laura Cereceda; Felipe Casado; Patrocinio Algara; David Oscier; Francisco J Menarguez; Juan F García; Miguel A Piris; Manuela Mollejo
Journal:  Haematologica       Date:  2017-05-18       Impact factor: 9.941

4.  CBL-MZ is not a single biological entity: evidence from genomic analysis and prolonged clinical follow-up.

Authors:  Helen Parker; Neil Robert McIver-Brown; Zadie A Davis; Marina Parry; Matthew J J Rose-Zerilli; Aliki Xochelli; Jane Gibson; Renata Walewska; Jonathan C Strefford; David G Oscier
Journal:  Blood Adv       Date:  2018-05-22

5.  Significant functional difference between TNFAIP3 truncation and missense mutants.

Authors:  Leire Escudero-Ibarz; Ming Wang; Ming-Qing Du
Journal:  Haematologica       Date:  2016-06-13       Impact factor: 9.941

Review 6.  Clinical impact of recurrently mutated genes on lymphoma diagnostics: state-of-the-art and beyond.

Authors:  Richard Rosenquist; Andreas Rosenwald; Ming-Qing Du; Gianluca Gaidano; Patricia Groenen; Andrew Wotherspoon; Paolo Ghia; Philippe Gaulard; Elias Campo; Kostas Stamatopoulos
Journal:  Haematologica       Date:  2016-09       Impact factor: 9.941

7.  Coactivation of NF-κB and Notch signaling is sufficient to induce B-cell transformation and enables B-myeloid conversion.

Authors:  Yan Xiu; Qianze Dong; Lin Fu; Aaron Bossler; Xiaobing Tang; Brendan Boyce; Nicholas Borcherding; Mariah Leidinger; José Luis Sardina; Hai-Hui Xue; Qingchang Li; Andrew Feldman; Iannis Aifantis; Francesco Boccalatte; Lili Wang; Meiling Jin; Joseph Khoury; Wei Wang; Shimin Hu; Youzhong Yuan; Endi Wang; Ji Yuan; Siegfried Janz; John Colgan; Hasem Habelhah; Thomas Waldschmidt; Markus Müschen; Adam Bagg; Benjamin Darbro; Chen Zhao
Journal:  Blood       Date:  2020-01-09       Impact factor: 22.113

Review 8.  Advances in targeted therapy for malignant lymphoma.

Authors:  Li Wang; Wei Qin; Yu-Jia Huo; Xiao Li; Qing Shi; John E J Rasko; Anne Janin; Wei-Li Zhao
Journal:  Signal Transduct Target Ther       Date:  2020-03-06

Review 9.  Advances in targeted therapy for malignant lymphoma.

Authors:  Li Wang; Wei Qin; Yu-Jia Huo; Xiao Li; Qing Shi; John E J Rasko; Anne Janin; Wei-Li Zhao
Journal:  Signal Transduct Target Ther       Date:  2020-03-06

10.  Genetic landscape of hepatitis B virus-associated diffuse large B-cell lymphoma.

Authors:  Weicheng Ren; Xiaofei Ye; Hong Su; Wei Li; Dongbing Liu; Mohammad Pirmoradian; Xianhuo Wang; Bo Zhang; Qiang Zhang; Longyun Chen; Man Nie; Yao Liu; Bin Meng; Huiqiang Huang; Wenqi Jiang; Yixin Zeng; Wenyu Li; Kui Wu; Yong Hou; Klas G Wiman; Zhiming Li; Huilai Zhang; Roujun Peng; Shida Zhu; Qiang Pan-Hammarström
Journal:  Blood       Date:  2018-03-15       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.